Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
With interest we read the article by Kong et al. about two SARS-CoV-2 infected patients with Takotsubo syndrome (TTS) complicated by cardiogenic shock [1]. Patient-1 (88yo male with metastatic prostate cancer) deceased but patient-2 (79yo female with multiple sclerosis) recovered [1]. It was concluded that TTS should remain on the differential in the setting of arrhythmias, systolic dysfunction, cardiac biomarker elevation, or ST-elevation [1]. We have the following comments and concerns.

The main shortcoming of the study is that the possible causes of TTS in the patients were not extensively discussed and that the pathophysiology of TTS remained elusive. Though it is mentioned that the SARS-CoV-2 induced cytokine storm may cause myocardial oedema, there was no evidence provided that either of the two patients had myocardial oedema. Other pathophysiological scenarios that should be considered in the context of a SARS-CoV-2 infection include myocarditis [2], secondary leading to TTS or autonomic dysfunction [3], leading to impaired sympathetic myocardial innervation. Since evidence is emerging that SARS-CoV-2 can trigger the development of Guillain Barre syndrome (GBS) [4] and GBS frequently affects the autonomic fibers, it is crucial that GBS is excluded in the two presented patients. GBS may develop within 10 to 90 days before or after onset of COVID-19 why it is conceivable that TTS can be an early complication of the viral infection. There is also increasing evidence that SARS-CoV-2 may cause myocarditis, why it is crucial that myocarditis is appropriately excluded. We should know if there was late enhancement on cardiac MRI or if endomyocardial biopsy was carried out in either patient.

Since TTS is a frequent complication of seizures and since cerebral metastasis complicated by seizures were not excluded in patient-1 and since multiple sclerosis may go along with seizures as well, it would be interesting to know if the history in either patient was positive for seizures. Single patients have been reported in whom multiple sclerosis per se was made responsible for the development of TTS.

Missing are the autopsy finding in patient-1 [1]. We should know if there was histological evidence for virus particles within the myocardium, the endocardium, the pericardium, or the cardiac conduction system, if there was an inflammatory response within the myocardium, or if there were micro-thrombi within the myocardial capillaries.

Missing is also the assessment of the severity of the COVID-19 infection. We should know if the severity of the viral infection was classified as mild, moderate, or severe.

We agree that the prevalence of TTS may be underestimated in COVID-19 patients. In a recent review, however, it was documented that as per the end of September 2020, only 38 patients with SARS-CoV-2 associated TTS have been reported [5]. In accordance with previous findings it was concluded that the general prevalence of TTS has not increased during the pandemic as reported by Jabri et al. and Delmas et al. [6,7], that the clinical presentation, epidemiology, treatment, and outcome of SARS-CoV-2-associated TTS is similar to COVID-19-unrelated TTS, and that TTS can mimic myocarditis [5].

Overall, the interesting report has some limitations, which should be addressed to strengthen the conclusions. Particularly, the pathophysiology of TTS in the two reported patients should be elucidated.

Declarations

Statement of ethics was in accordance if ethical guidelines.
Informed consent was obtained.
The study was approved by the institutional review board.

Funding sources

No funding was received.

Author contribution

JF: design, literature search, discussion, first draft, critical comments, final approval,

Declaration of competing interest

None.

https://doi.org/10.1016/j.carrev.2021.02.019
1553-8389/© 2021 Elsevier Inc. All rights reserved.
Acknowledgement

None.

References

[1] Kong N, Singh N, Mazzone S, Burkhardt R, Anchan R, Blair J. Takotsubo’s syndrome presenting as cardiogenic shock in patients with COVID-19: a case-series and review of current literature. Cardiovasc Revasc Med. 2021;28:50–3.

[2] Fadiran O. An atypical case of COVID-19 induced pancytopenia. Rhabdomyolysis and Myocarditis Cureus. 2021;13:e12455. https://doi.org/10.7759/cureus.12455.

[3] Chosh R, Roy D, Sengupta S, Benito-León J. Autonomic dysfunction heralding acute motor axonal neuropathy in COVID-19. J Neurovirol. 2020;26:964–6. https://doi.org/10.1007/s13365-020-00908-2.

[4] Finsterer J, Scorza FA, Fiorini AC. SARS-CoV-2-associated Guillain-Barre syndrome in 62 patients. Eur J Neurol. 2021;28:e10–2. https://doi.org/10.1111/ene.14544.

[5] Finsterer J, Stöllberger C. SARS-CoV-2 triggered Takotsubo in 38 patients. J Med Virol. 2020. https://doi.org/10.1002/jmv.26581.

[6] Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, et al. Incidence of stress cardiomyopathy during the coronavirus disease 2019 pandemic. JAMA Netw Open. 2020;3:e2014780. https://doi.org/10.1001/jamanetworkopen.2020.14780.

[7] Delmas C, Bouisset F, Lairez O. COVID-19 pandemic: no increase of takotsubo syndrome occurrence despite high-stress conditions. ESC Heart Fail. 2020;7:2143–5. https://doi.org/10.1002/ehf2.12871.